TR200200441T2 - ATP bağlayıcı kaset transportör protein ABC1' i kullanarak kolesterolün dışa akımını artırmak ve HDL' yi yükseltmek için terkipler ve yöntemler. - Google Patents
ATP bağlayıcı kaset transportör protein ABC1' i kullanarak kolesterolün dışa akımını artırmak ve HDL' yi yükseltmek için terkipler ve yöntemler.Info
- Publication number
- TR200200441T2 TR200200441T2 TR2002/00441T TR200200441T TR200200441T2 TR 200200441 T2 TR200200441 T2 TR 200200441T2 TR 2002/00441 T TR2002/00441 T TR 2002/00441T TR 200200441 T TR200200441 T TR 200200441T TR 200200441 T2 TR200200441 T2 TR 200200441T2
- Authority
- TR
- Turkey
- Prior art keywords
- abc1
- methods
- increasing
- compositions
- cholesterol
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title abstract 4
- 235000012000 cholesterol Nutrition 0.000 title abstract 3
- 102000043966 ABC-type transporter activity proteins Human genes 0.000 title 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 title 1
- 101000800403 Arabidopsis thaliana UPF0051 protein ABCI8, chloroplastic Proteins 0.000 title 1
- 102100030488 HEAT repeat-containing protein 6 Human genes 0.000 abstract 8
- 101000990566 Homo sapiens HEAT repeat-containing protein 6 Proteins 0.000 abstract 8
- 101000801684 Homo sapiens Phospholipid-transporting ATPase ABCA1 Proteins 0.000 abstract 8
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
Abstract
Bu bulus, yeni ABC1 polipeptidleri ve bunlari kodlayan nükleik asit molekülleri, ayrica ABC1 polinükleotidlerini ihtiva eden rekombinant vektörler, konak hücreler ve terkipler, ve ABC1 polipeptidlerini meydana getirmeye mahsus yöntemlerle ilgilidir. Bu bulus ayrica, ABC1 polipeptidlerine spesifik olarak baglanan antikorlar, kolesterolün disa akimini artirmak için yöntemler yani sira ABC14 in ekspresyonunu ve aktivitesini artirmaya mahsus yöntemler, ABC1 in ekspresyonunu modüle eden bilesikleri teshis etmek için yöntemler ve bir memelide, ABC1 polipeptidleri ve polinükleotidlerinin nisbi seviyesini belirlemek için yötemlerle ilgilidir. Bu bulus ayrica, bilesiklerin ABC1 ekspresyonunu modüle etme aktivitesini belirlemek belirlemek için kitler ve terkipler yani sira, bir bilesigin, kolesterolün ABC1 e bagimli disa ayarlayip ayarlamadigini belirlemek için uygun kitler ve terkipler de saglar.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14026499P | 1999-06-18 | 1999-06-18 | |
| US15387299P | 1999-09-14 | 1999-09-14 | |
| US16657399P | 1999-11-19 | 1999-11-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200200441T2 true TR200200441T2 (tr) | 2002-11-21 |
Family
ID=27385472
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2002/00441T TR200200441T2 (tr) | 1999-06-18 | 2000-06-16 | ATP bağlayıcı kaset transportör protein ABC1' i kullanarak kolesterolün dışa akımını artırmak ve HDL' yi yükseltmek için terkipler ve yöntemler. |
| TR2002/00440T TR200200440T2 (tr) | 1999-06-18 | 2000-06-16 | ATP Bağlayıcı Kaset Transporter Protein ABC1'i kullanarak kolesterolün dışa akımını artırmak ve HDL'yi yükseltmek için terkipler ve yöntemler |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2002/00440T TR200200440T2 (tr) | 1999-06-18 | 2000-06-16 | ATP Bağlayıcı Kaset Transporter Protein ABC1'i kullanarak kolesterolün dışa akımını artırmak ve HDL'yi yükseltmek için terkipler ve yöntemler |
Country Status (19)
| Country | Link |
|---|---|
| EP (2) | EP1218515B1 (tr) |
| JP (4) | JP2003508031A (tr) |
| KR (2) | KR20020012612A (tr) |
| CN (2) | CN100513570C (tr) |
| AR (2) | AR024576A1 (tr) |
| AT (1) | ATE422545T1 (tr) |
| AU (3) | AU5743400A (tr) |
| BR (2) | BR0011753A (tr) |
| CA (2) | CA2375781A1 (tr) |
| DE (1) | DE60041545D1 (tr) |
| HK (2) | HK1046427A1 (tr) |
| IL (2) | IL147021A0 (tr) |
| MX (2) | MXPA01013174A (tr) |
| NO (2) | NO20016114L (tr) |
| NZ (3) | NZ529785A (tr) |
| SG (2) | SG121853A1 (tr) |
| TR (2) | TR200200441T2 (tr) |
| TW (2) | TWI259205B (tr) |
| WO (2) | WO2000078971A2 (tr) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6617122B1 (en) | 1999-03-15 | 2003-09-09 | Xenon Genetics, Inc. | Process for identifying modulators of ABC1 activity |
| EP1854880A1 (en) * | 1999-03-15 | 2007-11-14 | University of British Columbia | Methods and reagents for modulating cholesterol levels |
| JP2004500332A (ja) * | 1999-07-08 | 2004-01-08 | テュラリク インコーポレイテッド | Ｈｄｌコレステロール値を上昇させる組成物および方法 |
| JP2003520780A (ja) * | 1999-09-01 | 2003-07-08 | ユニバーシティ オブ ブリティッシュ コロンビア | Ｈｄｌコレステロールとトリグリセリド水準を調節する組成物と方法 |
| US6555323B2 (en) * | 2000-02-08 | 2003-04-29 | Pfizer Inc. | Assay for ABCA1 |
| JP2003531613A (ja) | 2000-05-02 | 2003-10-28 | アバンテイス・フアルマ・エス・アー | Ａｂｃ１遺伝子の調節核酸配列 |
| EP1203588A1 (en) * | 2000-11-06 | 2002-05-08 | Bayer Ag | Sterol-independent regulation of ABC1 promoter via oncostatinM |
| US7033790B2 (en) | 2001-04-03 | 2006-04-25 | Curagen Corporation | Proteins and nucleic acids encoding same |
| WO2003004692A2 (en) * | 2001-07-03 | 2003-01-16 | Xenon Genetics, Inc. | Screening processes for agents modulating cholesterol levels |
| JPWO2003033023A1 (ja) * | 2001-10-12 | 2005-02-03 | グレラン製薬株式会社 | 低ｈｄｌ血症改善剤 |
| US6924311B2 (en) | 2001-10-17 | 2005-08-02 | X-Ceptor Therapeutics, Inc. | Methods for affecting various diseases utilizing LXR compounds |
| AU2002367060A1 (en) | 2001-12-21 | 2003-07-30 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| WO2003059884A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
| ATE496893T1 (de) | 2002-12-20 | 2011-02-15 | X Ceptor Therapeutics Inc | Isochinolinonderivate und deren verwendung als medikamente |
| JP4679517B2 (ja) | 2003-07-23 | 2011-04-27 | エグゼリクシス， インコーポレイテッド | 薬剤としてのアゼピン誘導体 |
| WO2005116057A1 (en) * | 2004-05-27 | 2005-12-08 | Baker Medical Research Institute | Monoclonal antibody against abca1 |
| WO2006122787A1 (en) | 2005-05-18 | 2006-11-23 | Ablynx Nv | Serum albumin binding proteins |
| ES2852423T3 (es) | 2005-05-20 | 2021-09-13 | Ablynx Nv | NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación |
| US8703805B2 (en) | 2005-06-27 | 2014-04-22 | Exelixis Patent Company Llc | Modulators of LXR |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| JP5227803B2 (ja) | 2006-11-24 | 2013-07-03 | ハイクス ラボラトリーズ合同会社 | スピロキノン化合物及び医薬組成物 |
| EP2102244A2 (en) | 2006-12-19 | 2009-09-23 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
| WO2008074839A2 (en) | 2006-12-19 | 2008-06-26 | Ablynx N.V. | Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders |
| EP2220120A2 (en) | 2007-11-27 | 2010-08-25 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| CN101965362A (zh) | 2008-03-05 | 2011-02-02 | 埃博灵克斯股份有限公司 | 新型抗原结合二聚体-复合物及其制备方法和应用 |
| AU2009235467A1 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Single variable domains against the Notch pathways |
| WO2010100135A1 (en) | 2009-03-05 | 2010-09-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| ES2610622T3 (es) * | 2009-03-31 | 2017-04-28 | The General Hospital Corporation | Regulación de microARN miR-33 en el tratamiento de trastornos relacionados con colesterol |
| NZ595461A (en) | 2009-04-10 | 2013-01-25 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| KR101676704B1 (ko) | 2009-05-28 | 2016-11-16 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | Ｌｘｒ 조절자 |
| WO2011045079A1 (en) | 2009-10-15 | 2011-04-21 | Intercell Ag | Hepatitis b virus specific human antibodies |
| EA202092589A3 (ru) | 2010-11-08 | 2021-06-30 | Аблинкс Н.В. | Cxcr2-связывающие полипептиды |
| TW201242953A (en) | 2011-03-25 | 2012-11-01 | Bristol Myers Squibb Co | Imidazole prodrug LXR modulators |
| IN2014CN00437A (tr) | 2011-06-23 | 2015-04-03 | Ablynx Nv | |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| JP2015521602A (ja) | 2012-06-14 | 2015-07-30 | アンブルックス, インコーポレイテッドAmbrx, Inc. | 核受容体リガンドポリペプチドに対して複合化されている抗ｐｓｍａ抗体 |
| US9101745B2 (en) * | 2013-03-14 | 2015-08-11 | Sonogene Llc | Sonochemical induction of ABCA1 expression and compositions therefor |
| JP6456909B2 (ja) | 2013-03-15 | 2019-01-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｘｒ調節因子 |
| JP6442475B2 (ja) | 2013-03-15 | 2018-12-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｌｘｒ調節因子 |
| NL1040254C2 (en) | 2013-05-17 | 2014-11-24 | Ablynx Nv | Stable formulations of immunoglobulin single variable domains and uses thereof. |
| GB201315136D0 (en) * | 2013-08-23 | 2013-10-09 | Univ Glasgow | Cholesterol modulation |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| WO2017089618A1 (en) | 2015-11-27 | 2017-06-01 | Ablynx Nv | Polypeptides inhibiting cd40l |
| US11098113B2 (en) | 2016-09-15 | 2021-08-24 | Vib Vzw | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
| CA3043515A1 (en) | 2016-11-16 | 2018-05-24 | Ablynx Nv | T cell recruiting polypeptides capable of binding cd123 and tcr alpha/beta |
| IL270908B1 (en) | 2017-06-02 | 2026-04-01 | Merck Patent Gmbh | ADAMTS-binding immunoglobulins |
| TW202428621A (zh) | 2017-06-02 | 2024-07-16 | 德商麥克專利有限公司 | 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽 |
| BR112019025097A2 (pt) | 2017-06-02 | 2020-07-28 | Merck Patent Gmbh | imunoglobulinas de ligação a mmp13 |
| EP3630818A1 (en) | 2017-06-02 | 2020-04-08 | Ablynx NV | Aggrecan binding immunoglobulins |
| JP2023516762A (ja) * | 2020-03-06 | 2023-04-20 | エンドリティクス テクノロジー インコーポレイテッド | 細胞内細菌感染症を治療するための組成物及び方法 |
| CN115433733B (zh) | 2021-06-04 | 2025-12-12 | 生物岛实验室 | 环状RNA Circ-ACE2翻译的多肽及其应用 |
| CN114369162B (zh) | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| JP2025523049A (ja) | 2022-07-14 | 2025-07-17 | バイオ－テラ ソリュ－ションズ，エルティーディー． | 抗Ｎｅｃｔｉｎ－４抗体及びその使用 |
| MA71603A (fr) | 2022-07-27 | 2025-05-30 | Ablynx Nv | Polypeptides se liant à un épitope spécifique du récepteur fc néonatal |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| JP2026506075A (ja) | 2023-02-17 | 2026-02-20 | アブリンクス エン．ヴェー． | 新生児型ｆｃ受容体に結合するポリペプチド |
| KR20260028051A (ko) | 2023-06-22 | 2026-03-03 | 아블린쓰 엔.브이. | 사이토카인의 수용체-활성을 조절하기 위한 키메라 단백질 |
| CN118027196B (zh) | 2023-06-25 | 2025-12-02 | 合肥天港免疫药物有限公司 | 抗cd3抗体及其应用 |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| CN119569886A (zh) | 2023-09-06 | 2025-03-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
| TW202511291A (zh) | 2023-09-11 | 2025-03-16 | 丹麥商諾佛 儂迪克股份有限公司 | 抗ｉｌ－６結構域之抗體 |
| US20250129145A1 (en) | 2023-09-22 | 2025-04-24 | Ablynx N.V. | Bi- and multivalent albumin binders |
| TW202543670A (zh) | 2023-12-22 | 2025-11-16 | 比利時商艾伯霖克斯公司 | 用於核內投予之基於蛋白質的接合載劑 |
| US20250236673A1 (en) | 2023-12-22 | 2025-07-24 | Ablynx N.V. | Protein-based carriers for site-specific amine conjugation |
| TW202602933A (zh) | 2024-03-28 | 2026-01-16 | 美商健臻公司 | 與轉鐵蛋白受體１的特異性表位結合的多肽 |
| US20260007757A1 (en) | 2024-06-18 | 2026-01-08 | Ablynx Nv | Antibody-recruiting molecules |
| WO2026078159A1 (en) | 2024-10-10 | 2026-04-16 | Ablynx Nv | Immune cell engagers and methods comprising the same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003531613A (ja) * | 2000-05-02 | 2003-10-28 | アバンテイス・フアルマ・エス・アー | Ａｂｃ１遺伝子の調節核酸配列 |
-
2000
- 2000-06-16 SG SG200307656A patent/SG121853A1/en unknown
- 2000-06-16 EP EP00942914A patent/EP1218515B1/en not_active Expired - Lifetime
- 2000-06-16 BR BR0011753-6A patent/BR0011753A/pt not_active Application Discontinuation
- 2000-06-16 WO PCT/US2000/016591 patent/WO2000078971A2/en not_active Ceased
- 2000-06-16 KR KR1020017016286A patent/KR20020012612A/ko not_active Ceased
- 2000-06-16 AT AT00942914T patent/ATE422545T1/de not_active IP Right Cessation
- 2000-06-16 AR ARP000103013A patent/AR024576A1/es unknown
- 2000-06-16 MX MXPA01013174A patent/MXPA01013174A/es unknown
- 2000-06-16 IL IL14702100A patent/IL147021A0/xx unknown
- 2000-06-16 SG SG200307655A patent/SG121852A1/en unknown
- 2000-06-16 CN CNB008091641A patent/CN100513570C/zh not_active Expired - Fee Related
- 2000-06-16 JP JP2001515880A patent/JP2003508031A/ja active Pending
- 2000-06-16 JP JP2001515881A patent/JP2003506097A/ja active Pending
- 2000-06-16 WO PCT/US2000/016765 patent/WO2000078972A2/en not_active Ceased
- 2000-06-16 AU AU57434/00A patent/AU5743400A/en not_active Abandoned
- 2000-06-16 EP EP00942867A patent/EP1190065A2/en not_active Withdrawn
- 2000-06-16 NZ NZ529785A patent/NZ529785A/en unknown
- 2000-06-16 TR TR2002/00441T patent/TR200200441T2/tr unknown
- 2000-06-16 MX MXPA01013175A patent/MXPA01013175A/es active IP Right Grant
- 2000-06-16 NZ NZ516061A patent/NZ516061A/en unknown
- 2000-06-16 AU AU57467/00A patent/AU777461B2/en not_active Ceased
- 2000-06-16 DE DE60041545T patent/DE60041545D1/de not_active Expired - Fee Related
- 2000-06-16 CA CA002375781A patent/CA2375781A1/en not_active Abandoned
- 2000-06-16 KR KR10-2001-7016284A patent/KR100476519B1/ko not_active Expired - Fee Related
- 2000-06-16 CA CA002375787A patent/CA2375787C/en not_active Expired - Fee Related
- 2000-06-16 CN CN00809163A patent/CN1379817A/zh active Pending
- 2000-06-16 HK HK02107131.3A patent/HK1046427A1/zh unknown
- 2000-06-16 AR ARP000103012A patent/AR024391A1/es unknown
- 2000-06-16 HK HK02108234.7A patent/HK1046708A1/zh unknown
- 2000-06-16 IL IL14702200A patent/IL147022A0/xx unknown
- 2000-06-16 TR TR2002/00440T patent/TR200200440T2/tr unknown
- 2000-06-16 BR BR0011696-3A patent/BR0011696A/pt not_active IP Right Cessation
- 2000-06-16 NZ NZ531401A patent/NZ531401A/en unknown
- 2000-08-25 TW TW089111924A patent/TWI259205B/zh not_active IP Right Cessation
- 2000-08-25 TW TW095113205A patent/TWI304737B/zh active
-
2001
- 2001-12-14 NO NO20016114A patent/NO20016114L/no unknown
- 2001-12-14 NO NO20016121A patent/NO20016121L/no not_active Application Discontinuation
-
2004
- 2004-11-04 JP JP2004320358A patent/JP4277956B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-14 AU AU2005200171A patent/AU2005200171A1/en not_active Abandoned
- 2005-10-26 JP JP2005311515A patent/JP2006137750A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR200200441T2 (tr) | ATP bağlayıcı kaset transportör protein ABC1' i kullanarak kolesterolün dışa akımını artırmak ve HDL' yi yükseltmek için terkipler ve yöntemler. | |
| Safer et al. | Thymosin β4 binds actin in an extended conformation and contacts both the barbed and pointed ends | |
| Kerlavage et al. | Covalent modification of an adenosine 3': 5'-monophosphate binding site of the regulatory subunit of cAMP-dependent protein kinase II with 8-azidoadenosine 3': 5'-monophosphate. Identification of a single modified tyrosine residue. | |
| Thelander | Physicochemical characterization of ribonucleoside diphosphate reductase from Escherichia coli | |
| Boulanger et al. | Characterization of adenovirus protein IX | |
| Sebastiano et al. | A new deuterated alkylating agent for quantitative proteomics | |
| DE69216478D1 (de) | Sequenz-spezifische DNS-Bindung durch P53 | |
| CA2413857A1 (en) | Pd-l2 molecules: pd-1 ligands and uses therefor | |
| DE60234131D1 (de) | Neue fusionsproteine und molekulare bindungsassays | |
| ATE426018T1 (de) | Pca3, pca3-gene und verfahren zu ihrer verwendung | |
| Huse et al. | Semisynthesis of hyperphosphorylated type I TGFβ receptor: addressing the mechanism of kinase activation | |
| DK0930366T3 (da) | Bindingsdomæner i Delta-proteiner | |
| NZ323795A (en) | Isolated nucleic acid molecules encoding AUR-1 (aurora-1) and AUR-2 polypeptides | |
| BR9712298A (pt) | Polipeptìdeo, molécula de dna, vetor de expressão recombinante, célula hospedeira, processo para detectar infecção por m. tuberculosis em uma amostra biológica, kit diagnóstico, anticorpos monoclonal, e, policlonal, e, proteìna de fusão | |
| Casbarra et al. | Conformational analysis of HAMLET, the folding variant of human α‐lactalbumin associated with apoptosis | |
| AU3618095A (en) | Alk-7 (activin like kinase), a serine threonine kinase receptor | |
| Grammer et al. | Chemistry and mechanism of vanadate-promoted photooxidative cleavage of myosin | |
| TR200003624T2 (tr) | Yeni poli(ADP-RİBOZ) polimeraz-genleri | |
| Johnson et al. | Involvement of an arginine residue of actin in tropomyosin binding | |
| SE9801148D0 (sv) | New receptors | |
| Mole | A genetic marker in the variable region of rabbit immunoglobulin heavy chain | |
| Lim et al. | The K15 protein of Kaposi's sarcoma-associated herpesvirus recruits the endocytic regulator intersectin 2 through a selective SH3 domain interaction | |
| WO2003008626A3 (en) | Novel human nucleic acids encoding a pantothenate kinase and methods of use | |
| Sun et al. | Mass spectrometric characterization of mitochondrial electron transport complexes: subunits of the rat heart ubiquinol–cytochrome c reductase | |
| Meades et al. | Association of the 17-kDa extrinsic protein with photosystem II in higher plants |